Citations (41)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Ricardo Viana, Shelialah Pereira, Swati Mehta, Thomas Miller & Robert Teasell. (2012) Evidence for Therapeutic Interventions for Hemiplegic Shoulder Pain During the Chronic Stage of Stroke: A Review. Topics in Stroke Rehabilitation 19:6, pages 514-522.
Read now
Read now
Jörg Jerosch & Manfred Söhling. (2012) Open-label, Multicenter, Randomized Study Investigating the Efficacy and Safety of Botulinum Toxin Type A in the Treatment of Myofascial Pain Syndrome in the Neck and Shoulder Girdle. Journal of Musculoskeletal Pain 20:2, pages 95-99.
Read now
Read now
Paul S Yamauchi. (2010) Selection and preference for botulinum toxins in the management of photoaging and facial lines: patient and physician considerations. Patient Preference and Adherence 4, pages 345-354.
Read now
Read now
Anne Marie Tremaine & Jerry L McCullough. (2010) Botulinum toxin type A for the management of glabellar rhytids. Clinical, Cosmetic and Investigational Dermatology 3, pages 15-23.
Read now
Read now
Articles from other publishers (37)
Olivia Samotus & Mandar Jog. (2023)
Conversion to
AbobotulinumtoxinA
Increases Waning Time and Efficacy for Cervical Dystonia
. Movement Disorders Clinical Practice 10:5, pages 756-763.
Crossref
Crossref
Joshua A. Vova, Michael M. Green, Joline E. Brandenburg, Loren Davidson, Andrea Paulson, Supreet Deshpande, Joyce L. Oleszek, Didem Inanoglu & Matthew J. McLaughlin. (2021) A consensus statement on the use of botulinum toxin in pediatric patients. PM&R 14:9, pages 1116-1142.
Crossref
Crossref
Kirsten Platho-Elwischger, Michaela Schmoeger, Ulrike Willinger, Carmen Abdel-Aziz, Jennifer Algner, Sandra Pretscherer, Eduard Auff, Gottfried Kranz, Oliver Turnbull & Thomas Sycha. (2022) Cognitive Performance After Facial Botulinum Toxin Treatment in a Cohort of Neurologic Patients: An Exploratory Study. Archives of Physical Medicine and Rehabilitation 103:3, pages 402-408.
Crossref
Crossref
Rajat Kandhari, Al Imran, Nitin Sethi, Eqram Rahman & Afshin Mosahebi. (2021) Onabotulinumtoxin Type A Dosage for Upper Face Expression Lines in Males: A Systematic Review of Current Recommendations. Aesthetic Surgery Journal 41:12, pages 1439-1453.
Crossref
Crossref
Ali P. Mourad, Marie Shella De Robles & Robert D. Winn. (2020) Low-Dose Pre-Operative Botulinum Toxin A Effectively Facilitates Complex Ventral Hernia Repair: A Case Report and Review of the Literature. Medicina 57:1, pages 14.
Crossref
Crossref
Mark S. Nestor, David Arnold & Daniel Fischer. (2020) The mechanisms of action and use of botulinum neurotoxin type A in aesthetics: Key Clinical Postulates II. Journal of Cosmetic Dermatology 19:11, pages 2785-2804.
Crossref
Crossref
Heakyung Kim, Eduardo Del Rosario, Richard Anderson, Nicole Bainton, Jared Levin & Angeline Bowman. 2020. Orthopedic Care of Patients with Cerebral Palsy. Orthopedic Care of Patients with Cerebral Palsy
29
50
.
Anna Kutschenko, Hans Bigalke, Florian Wegner & Kai Wohlfarth. (2019) The role of human serum albumin and neurotoxin associated proteins in the formulation of BoNT/A products. Toxicon 168, pages 158-163.
Crossref
Crossref
Raffaela Pero, Sonia Laneri & Giovanna Fico. 2018. Botulinum Toxin. Botulinum Toxin.
Kristina Tedroff, Gustaf Befrits, Carl Johan Tedroff & Stefan Gantelius. (2018) To switch from Botox to Dysport in children with CP, a real world, dose conversion, cost-effectiveness study. European Journal of Paediatric Neurology 22:3, pages 412-418.
Crossref
Crossref
Daniel J. Ozzello & Joseph N. Giacometti. (2018) Botulinum Toxins for Treating Essential Blepharospasm and Hemifacial Spasm. International Ophthalmology Clinics 58:1, pages 49-61.
Crossref
Crossref
Michael A.C. Kane. 2018. Master Techniques in Facial Rejuvenation. Master Techniques in Facial Rejuvenation
55
67.e1
.
Mark S. NestorRaymond E. KleinfelderAndy Pickett. (2017) The Use of Botulinum Neurotoxin Type A in Aesthetics: Key Clinical Postulates. Dermatologic Surgery 43:3, pages S344-S362.
Crossref
Crossref
O. R. Orlova, S. L. Timerbaeva, S. E. Khatkova, E. V. Kostenko, D. A. Krasavina & D. V. Zakharov. (2017) Conversion ratio between different botulinum neuroprotein product in neurological practice. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 117:9, pages 132.
Crossref
Crossref
Alisa A Sharova. (2016) Comparison of different consensuses of BTXA in different countries. Journal of Cosmetic Dermatology 15:4, pages 540-548.
Crossref
Crossref
Anna Kutschenko, Anja Manig, Marie-Christine Reinert, Angelika Mönnich & David Liebetanz. (2016) In-vivo comparison of the neurotoxic potencies of incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA. Neuroscience Letters 627, pages 216-221.
Crossref
Crossref
Adriana Hernández López & Estefanía J. Villalobos Rubalcava. (2016) Infiltración de toxina botulínica en la preparación preoperatoria de las hernias con defectos de 10cm (y hasta 15cm). Revista Hispanoamericana de Hernia 4:2, pages 43-49.
Crossref
Crossref
Francesco Scaglione. (2016) Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice. Toxins 8:3, pages 65.
Crossref
Crossref
Vito Pavone, Gianluca Testa, Domenico A. Restivo, Luca Cannavò, Giuseppe Condorelli, Nicola M. Portinaro & Giuseppe Sessa. (2016) Botulinum Toxin Treatment for Limb Spasticity in Childhood Cerebral Palsy. Frontiers in Pharmacology 7.
Crossref
Crossref
Alberto Albanese, Giovanni Abbruzzese, Dirk Dressler, Wojciech Duzynski, Svetlana Khatkova, Maria Jose Marti, Pablo Mir, Cesare Montecucco, Elena Moro, Michaela Pinter, Maja Relja, Emmanuel Roze, Inger Marie Skogseid, Sofiya Timerbaeva & Charalampos Tzoulis. (2015) Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement. Journal of Neurology 262:10, pages 2201-2213.
Crossref
Crossref
Walter Strobl, Tim Theologis, Reinald Brunner, Serdar Kocer, Elke Viehweger, Ignacio Pascual-Pascual & Richard Placzek. (2015) Best Clinical Practice in Botulinum Toxin Treatment for Children with Cerebral Palsy. Toxins 7:5, pages 1629-1648.
Crossref
Crossref
Ji Young Yun, Jae Woo Kim, Hee‐Tae Kim, Sun Ju Chung, Jong‐Min Kim, Jin Whan Cho, Jee‐Young Lee, Ha Neul Lee, Sooyeoun You, Eungseok Oh, Heejeong Jeong, Young Eun Kim, Han‐Joon Kim, Won Yong Lee & Beom S. Jeon. (2014) Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: A double‐blind, randomized study. Movement Disorders 30:2, pages 206-213.
Crossref
Crossref
Robert Gerwin. 2015. Treatment of Chronic Pain by Interventional Approaches. Treatment of Chronic Pain by Interventional Approaches
359
369
.
Michel R. Popoff & Chloé Connan. 2014. Molecular Aspects of Botulinum Neurotoxin. Molecular Aspects of Botulinum Neurotoxin
35
68
.
Roberta Ravenni, Domenico De Grandis & Alberto Mazza. (2013) Conversion ratio between Dysport and Botox in clinical practice: an overview of available evidence. Neurological Sciences 34:7, pages 1043-1048.
Crossref
Crossref
Alastair Carruthers, Michael A. C. Kane, Timothy C. Flynn, Peter Huang, Sang D. Kim, Nowell Solish & Gina Kaeuper. (2013) The Convergence of Medicine and Neurotoxins: A Focus on Botulinum Toxin Type A and Its Application in Aesthetic Medicine—A Global, Evidence-Based Botulinum Toxin Consensus Education Initiative. Dermatologic Surgery 39:3, pages 493-509.
Crossref
Crossref
Jack J. ChenKhashayar Dashtipour. (2013) Abo‐, Inco‐, Ona‐, and Rima‐Botulinum Toxins in Clinical Therapy: A Primer. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 33:3, pages 304-318.
Crossref
Crossref
Myung Eun Chung, Dae Heon Song & Joo Hyun Park. (2013) Comparative Study of Biological Activity of Four Botulinum Toxin Type A Preparations in Mice. Dermatologic Surgery 39:1, pages 155-164.
Crossref
Crossref
Robert Gerwin. 2013. Comprehensive Treatment of Chronic Pain by Medical, Interventional, and Integrative Approaches. Comprehensive Treatment of Chronic Pain by Medical, Interventional, and Integrative Approaches
563
573
.
F. Mark Dunning, Daniel R. Ruge, Timothy M. Piazza, Larry H. Stanker, Füsûn N. Zeytin & Ward C. Tucker. (2012) Detection of Botulinum Neurotoxin Serotype A, B, and F Proteolytic Activity in Complex Matrices with Picomolar to Femtomolar Sensitivity. Applied and Environmental Microbiology 78:21, pages 7687-7697.
Crossref
Crossref
Andy Pickett. (2012) Inability of Speculation to Explain Dose Effect Differences Between
Botulinum Toxin Products. Archives of Facial Plastic Surgery 14:6, pages 467-468.
Crossref
Crossref
Doris Hexsel, Cristiano Brum, Débora Zechmeister do Prado, Mariana Soirefmann, Francisco Telechea Rotta, Taciana Dal’Forno & Ticiana C. Rodrigues. (2012) Field effect of two commercial preparations of botulinum toxin type A: A prospective, double-blind, randomized clinical trial. Journal of the American Academy of Dermatology 67:2, pages 226-232.
Crossref
Crossref
Mark Stacy & Patrick Hickey. 2012. Handbook of Dystonia. Handbook of Dystonia
413
435
.
Altaf Mangera, Karl-Erik Andersson, Apostolos Apostolidis, Chris Chapple, Prokar Dasgupta, Antonella Giannantoni, Stavros Gravas & Stephan Madersbacher. (2011) Contemporary Management of Lower Urinary Tract Disease With Botulinum Toxin A: A Systematic Review of Botox (OnabotulinumtoxinA) and Dysport (AbobotulinumtoxinA). European Urology 60:4, pages 784-795.
Crossref
Crossref
Tony Zhang, Aleem Adatia, Wasifa Zarin, Misha Moitri, Abi Vijenthira, Rong Chu, Lehana Thabane & Walter Kean. (2010) The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis. Inflammopharmacology 19:1, pages 21-34.
Crossref
Crossref
Katja Kollewe, Bahram Mohammadi, Reinhard Dengler & Dirk Dressler. (2010) Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox® or Dysport®. Journal of Neural Transmission 117:6, pages 759-763.
Crossref
Crossref
Jarosław Sławek, Halina Car, Marcin Bonikowski, Andrzej Bogucki, Dariusz Koziorowski, Anna Potulska-Chromik & Monika Rudzińska. (2010) Czy wszystkie preparaty toksyny botulinowej typu A są takie same? Porównanie trzech preparatów toksyny botulinowej typu A w zarejestrowanych wskazaniach w neurologii. Neurologia i Neurochirurgia Polska 44:1, pages 43-64.
Crossref
Crossref